Beijing, People's Republic of China, Asia, Blood Cells, Cancer, Health and Medicine, Hematology, Hemic and Immune Systems, Immune System, Immunology, Immunoproliferative Disorders, Information Technology, Leukocytes, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Natural Killer T-Cells, Oncology, Risk and Prevention, T-Cell Lymphoma, T-Lymphocytes Keywords: Beijing; People's Republic of China; Asia; Blood Cells; Cancer; Health and Medicine; Hematology; Hemic and Immune Systems; Immune System; Immunology; Immunoproliferative Disorders; Information Technology; Leukocytes; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Natural Killer T-Cells; Oncology; Risk and Prevention; T-Cell Lymphoma; T-Lymphocytes EN Beijing People's Republic of China Asia Blood Cells Cancer Health and Medicine Hematology Hemic and Immune Systems Immune System Immunology Immunoproliferative Disorders Information Technology Leukocytes Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Natural Killer T-Cells Oncology Risk and Prevention T-Cell Lymphoma T-Lymphocytes 970 970 1 11/06/23 20231110 NES 231110 2023 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Oncology - T-Cell Lymphoma have been presented. [Extracted from the article]